IQ-AI Limited (GB:IQAI) has released an update.
IQ-AI Limited reports a revenue increase to £609k for the year ended December 31, 2023, up from £536k the previous year, marking a year of strategic regulatory milestones and product advancements. The company also entered into a global distribution agreement with GE Healthcare and expanded its imaging product sales by 23%. A primary operational focus for 2024 is the Expanded Access Program for their oral brain cancer drug candidate, IB003, aimed at broadening patient treatment options.
For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.
